Neri 2016.

Methods	RCT (open‐label). Design: parallel. Location: multicentre (6 centres) in Italy. Duration: 21 days treatment with follow up to 6 months.
Participants	People with CF over 4 years of age with first or new MRSA infection, not infected by B cepacia complex and with no clinical signs of respiratory exacerbation and who could demonstrate regular visits to the centre. From 2013, 61 participants randomised: 29 to treatment arm and 32 to control arm. Mean age 19.1 (12.9) years.
Interventions	Eradication protocol: an association of antibiotics according to susceptibility pattern (oral co‐trimoxazole and rifampicin for 21 days associated with intranasal mupirocin for 5 days). Control group: observation only.
Outcomes	Successful eradication or failure, where successful eradication is defined as the absence of MRSA following antibiotic treatment in at least 3 antibiograms over a period of 6 months.
Notes	Awaiting data analysis and full publication.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were "randomly" assigned to active treatment arm or observation only arm. However, the procedure for randomisation is unclear from the abstract.
Allocation concealment (selection bias)	Unclear risk	Not discussed in abstract.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label trial.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not discussed in abstract
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear from abstract data.
Selective reporting (reporting bias)	Unclear risk	Original protocol not published.
Other bias	Unclear risk	Unclear from abstract data

B cepacia: Burkholderia cepacia
 CF: cystic fibrosis
 IV: intravenous
 MRSA: meticillin‐resistant Staphyloccocus aureus
 RCT: randomised controlled trial
 TMP‐SMX: trimethoprim‐sulfamethoxazole